Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer

Key facts

Sponsor

Alliance for Clinical Trials in Oncology

Principal Investigator

Steven R. Alberts, MD, M.D., Ph.D

Mayo Clinic

Intervention

docetaxel(drug)

Enrollment

25 enrolled

Eligibility

18 years · All sexes

Timeline

2001 – 2008

Study locations (17)

• CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
• Mayo Clinic, Jacksonville, Florida, United States
• CCOP - Atlanta Regional, Atlanta, Georgia, United States
• MBCCOP - Hawaii, Honolulu, Hawaii, United States
• CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
• CCOP - Carle Cancer Center, Urbana, Illinois, United States
• CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
• CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
• Siouxland Hematology-Oncology, Sioux City, Iowa, United States
• CCOP - Wichita, Wichita, Kansas, United States
• CCOP - Duluth, Duluth, Minnesota, United States
• Mayo Clinic Cancer Center, Rochester, Minnesota, United States
• Medcenter One Health System, Bismarck, North Dakota, United States
• CCOP - Toledo Community Hospital, Toledo, Ohio, United States
• CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
• +2 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →